NCT06891833 2025-10-02A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerSichuan Baili Pharmaceutical Co., Ltd.Phase 2/3 Recruiting120 enrolled
NCT05426486 2024-10-30A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsShengjing HospitalPhase 2/3 Active not recruiting136 enrolled
NCT05189067 2022-01-12Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast CancerSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2/3 Unknown190 enrolled